Welcome, Guest. Please login or register.
June 22, 2024, 04:03:04 pm

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55129
  • Total Topics: 4851
  • Online Today: 117
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 73
Total: 73


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Opdivo Immunotherapy Improves Survival for People With Liver Cancer  (Read 8650 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
The checkpoint inhibitor Opdivo (nivolumab), which helps the immune system fight cancer, led to tumor shrinkage or stable disease in more than half of treated patients with liver cancer, according to results from the Checkmate 040 trial presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting, held last week in Washington, DC.

These extended follow-up results were the basis for the Food and Drug Administration’s September approval of Opdivo for the treatment of people with liver cancer who previously used the kinase inhibitor Nexavar (sorafenib), the only approved first-line therapy, according to Bristol-Myers Squibb.


Offline Anne A

  • Member
  • Posts: 31
  • my Rubicon
Re: Opdivo Immunotherapy Improves Survival for People With Liver Cancer
« Reply #1 on: December 26, 2017, 03:04:03 pm »
Good news
Female,67, treatment naive,Geno type 1, Diagnosed 2000,contracted late 1960s,AST108(10-35 u/l)ALT 58(6-29 U/L)Platelet-90


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.